NAVIDEA BIOPHARMACEUTICALS, INC. NAVB Cash Flow

Navidea biopharmaceuticals, inc. (NAVB)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-2,673	-2,771	-3,074	-2,673	-2,429	-3,160	-3,821	-2,394	-6,737	-4,058	-1,389	-5,187	85,581	-3,881	-59	-6,681	-3,686	-2,510	-8,071	-9,690	-7,291	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,222	-11,740	-	-11,306	-10,300	-7,341	-7,234	-9,098	-5,834	-6,989	-7,607	19,831	-2,188	-4,422
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
16	-4	34	36	36	7	37	37	37	20	50	75	86	117	111	117	149	131	132	149	149	127	125	124	111	-	-	-	-	-	-	-	-	-	-	50	59
Loss on disposal and abandonment of patents and equipment
-	-	-	-	-	-	-	-	-	-0	0	-706	-100	0	-150	13	0	0	-18	-9	-5	-	-	-	-	-	-	-	-	-	-	-	-	-0	0	-4	-14
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85	158	76	-	52	53	33	-	-	-	-
Loss on disposal and abandonment of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17	-10	-	-1	0	0	-	-	-	-	-	-	-	-
Change in inventory reserve
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-46	27	-120	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount and issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	5	72	69	64	146	212	206	200	194	241	263	258	120	122	-	146	144	116	-	-	-	-
Compounded interest on long term debt
-	-	-	-	-	-	-	-	41	53	28	39	143	194	190	351	824	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock compensation expense
39	53	50	66	61	45	44	79	137	74	63	109	147	-33	49	-79	340	452	397	412	1,106	601	-527	866	693	714	771	679	742	581	588	715	418	519	1,788	279	1,004
Equity in loss of R-NAV, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-262	-261	-262	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Equity in loss of R-NAV, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of financial instruments
-	-	-	-	-	-	-	-	-	0	0	12	140	1,102	-839	1,469	1,125	1,088	-1,577	-1,852	1,727	-1,232	-409	-92	392	265	-377	0	0	-	-	-	-	-	-	-	-
Change in fair value of financial instruments
-	-	-	-	-	-	-	-	-	0	0	12	140	-	-	-	-	-	-	-	-	-1,232	-409	-92	392	-	-377	0	0	-	-	-	-	-	-	-	-
Change in fair value of financial instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-92	-184	4	7	-10	-953
Loss on extinguishment of debt
-	-	-	-	-	-1,026	0	0	-4,265	-2,887	0	0	-1,314	-	-	-	-	-	-	-	-	0	0	0	-2,610	0	0	-1,372	0	-	-	-	-	-	-	-	-
Value of stock issued to directors
-	-	-	-	-	-	-	-	-	0	0	0	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of stock issued in payment of employee bonuses
64	-	-	-	-	300	0	151	165	0	0	1	367	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of stock issued to 401(k) plan for employer matching contributions
-	-	-	-	-	0	0	0	35	0	0	53	0	-	-	-	-	0	0	0	117	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued warrants in connection with Asset Sale
-	-	-	-	-	-	-	-	-	0	0	0	3,337	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of restricted stock issued to directors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of stock issued to employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of stock issued in payment of services
4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	15	0	-12	12	-	-	-	-48	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued stock to 401(k) plan for employer matching contributions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	0	-	0	0	66	-	0	50	0	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Issuance of common stock to 401(k) Plan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48
Accounts and other receivables
-860	-56	-61	196	-11	-65	-286	-12,581	7	-1,540	-1,956	-178	14,821	-1,672	-28	721	-903	1,699	95	618	394	-648	978	-99	-563	-	-17	68	-2	-4	14	-17	0	-59	290	211	-223
Inventory
-	-	-	-	-	-	-	-	-	0	0	-0	-1,470	665	78	-129	246	-219	-271	595	-240	-187	-246	-208	-118	189	713	462	569	-343	-277	0	96	-22	-130	149	57
Prepaid expenses, right-of-use lease assets, and other assets
-69	56	-788	-182	217	-173	-260	-320	-50	1,429	-298	-262	65	-175	108	74	-193	325	91	-660	-20	367	303	-116	-78	218	-794	370	121	616	-515	151	132	235	-61	-54	-79
Accounts payable
342	273	165	-179	427	-190	161	-246	-154	-120	-394	-1,665	-3,837	2,228	-154	2,233	1,133	468	-58	-548	428	-899	702	-752	3	716	-1,182	1,022	447	-553	991	187	110	-612	17	720	-664
Accrued, lease and other liabilities
324	-412	124	148	-56	-443	1,104	-33	-79	-740	-1,559	-229	-3,719	1,237	2,252	1,856	4	-587	682	-1,051	673	-23	-489	734	-1,471	2,313	1,190	493	-821	-30	615	-224	-235	-829	-38	543	812
Deferred revenue
-	-	-	-	-	-	-	-	-15	0	0	0	-2,315	2,300	-666	-263	-265	-182	-247	-250	1,916	-	-	0	0	-	-	-	-	-	-	-	-	-53	-86	91	158
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,679	-	-4,089	-6,682	-4,109	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-951	-2,733	-2,342	-2,113	-2,165	-2,127	-1,887	10,549	-2,259	-1,962	-946	-5,666	67,658	-	-	-	-	-	-	-	-	-	-	-8,420	-9,172	-	-9,705	-7,355	-7,395	-7,318	-5,063	-4,949	-6,591	-9,714	-3,709	-795	-1,789
Cash flows from investing activities:
Maturities of available-for-sale securities
-	0	200	0	200	400	200	400	400	200	200	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Payments for purchases) proceeds from disposal of equipment
-6	-	-	-	26	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Patent and trademark costs
57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1	-	-	-	-	3	3	122	985	476	90	316	355	45	242	233	141	88	15	23	56
Proceeds from sales of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-17	0	-20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sales of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Patent and trademark costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	17	4	5	25	37	7	7	24	11	15	1	2	2	3	0	-0	48	0	4
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-	-1	-31	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-64	-57	201	400	226	-26	-16	596	400	197	-23	-2,008	0	-	-	-	-	-	-	-	-	-	-	-129	-992	-	-102	-332	-356	-48	-245	-236	-141	67	27,174	-22	-61
Cash flows from financing activities:
Proceeds from issuance of common stock
850	1,040	0	5,996	50	0	3,000	0	0	18	0	0	54	13	0	0	0	0	5	60	0	0	-0	33	54	0	29,999	5,103	6,200	1,965	214	366	177	64	827	1,117	5,189
Proceeds from issuance of MT Preferred Stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	500	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of common stock issuance costs
150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,049	343	324	-	-	-	0	-	-	-	-
Payment of tax withholdings related to stock-based compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54	0	4	70	0	0	0	659	0	0	3	4	-	-	-	-
Payment of preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	25	25	25	25	25	25	25
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	51,500	3,000	0	0	0	30,000	0	0	25,000	4,000	-	-	-	0	-	-	-	-
Payment of debt-related costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	12	1,750	0	66	1,111	0	0	0	0	153	-	-	-	-
Payment of debt-related costs
-	-	-	-	-	-	-	-	-	0	0	0	1,314	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on notes payable
130	42	80	118	117	77	80	119	118	78	44	132	59,498	42	0	189	0	-	-	-	-	0	0	0	25,000	-0	80	5,165	735	-	-	-	0	0	9	26	26
Restricted cash held for payment against debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-1,500	-3,000	-500	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments under capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	1	2	2	2	1	1	1	1	1	1	3	3
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-	-328	17,620	3,499	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
569	997	-80	5,305	-66	-77	2,919	-7,272	-118	-60	-44	-131	-60,758	-	-	-	-	-	-	-	-	-	-	15	3,232	-	28,801	23,480	8,479	5,274	-432	235	-7	6,527	755	-1,342	5,134
Net decrease in cash and cash equivalents
-445	-1,794	-2,221	3,592	-2,005	-2,231	1,016	3,873	-1,977	-1,824	-1,014	-7,806	6,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	728	-345	-4,328	-1,682	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,160	3,283
Net (decrease) increase in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-594	-	-7,083	-8,534	-6,932	-11,693	18,994	15,792	727	-2,092	-5,741	-4,951	-6,739	-	-	-	-